GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Hyundai Pharmaceutical Co Ltd (XKRX:004310) » Definitions » Net Income From Continuing Operations

Hyundai Pharmaceutical Co (XKRX:004310) Net Income From Continuing Operations : ₩2,708 Mil (TTM As of May. 2024)


View and export this data going back to 1978. Start your Free Trial

What is Hyundai Pharmaceutical Co Net Income From Continuing Operations?

Net Income From Continuing Operations indicates the net income that a firm brings in from ongoing business activities. These activities are expected to continue into the next reporting period. Hyundai Pharmaceutical Co's net income from continuing operations for the three months ended in May. 2024 was ₩1,082 Mil. Its net income from continuing operations for the trailing twelve months (TTM) ended in May. 2024 was ₩2,708 Mil.

Hyundai Pharmaceutical Co Net Income From Continuing Operations Historical Data

The historical data trend for Hyundai Pharmaceutical Co's Net Income From Continuing Operations can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Hyundai Pharmaceutical Co Net Income From Continuing Operations Chart

Hyundai Pharmaceutical Co Annual Data
Trend Nov14 Nov15 Nov16 Nov17 Nov18 Nov19 Nov20 Nov21 Nov22 Nov23
Net Income From Continuing Operations
Get a 7-Day Free Trial Premium Member Only Premium Member Only 1,212.85 2,187.06 -3,173.18 -164.58 6,121.76

Hyundai Pharmaceutical Co Quarterly Data
Aug19 Nov19 Feb20 May20 Aug20 Nov20 Feb21 May21 Aug21 Nov21 Feb22 May22 Aug22 Nov22 Feb23 May23 Aug23 Nov23 Feb24 May24
Net Income From Continuing Operations Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 3,132.62 1,748.32 -430.92 309.18 1,081.80

Hyundai Pharmaceutical Co Net Income From Continuing Operations Calculation

Net Income From Continuing Operations indicates the net income that a firm brings in from ongoing business activities. These activities are expected to continue into the next reporting period. It excludes extraordinary items, income from the cumulative effects of accounting changes, non-recurring items, income from tax loss carry forward, and preferred dividends.

Net Income From Continuing Operations for the trailing twelve months (TTM) ended in May. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was ₩2,708 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Hyundai Pharmaceutical Co Business Description

Industry
GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Hyundai Pharmaceutical Co Ltd (XKRX:004310) » Definitions » Net Income From Continuing Operations
Comparable Companies
XKRX:002800 XKRX:002720 XKRX:183490 XKRX:063160 XKRX:072020 XKRX:067290 XKRX:000230 XKRX:106190 XKRX:009300 XKRX:330350 ZTS XTER:MRK TSE:4502 LSE:HLN NSE:SUNPHARMA TSE:4523 TSE:4507 SZSE:000538 XSWX:SDZ HKSE:03692
Traded in Other Exchanges
N/A
Address
Bonegeunsa Street 135, Hyundai Pharm Building, Gangnam-gu, Seoul, KOR, 135-545
Website
http://www.hyundaipharm.co.kr
Hyundai Pharmaceutical Co Ltd is a South Korea based company engage in the manufacturing and distribution of pharmaceutical products, health foods, and medical equipment.

Hyundai Pharmaceutical Co Headlines

No Headlines